Bristol Myers Squibb exterior sign
BMS has released its terms of use for the claims data providers must give it in exchange for access to 340B pricing on Revlimid, Pomalyst, and Thalomid.

BMS Fleshes Out How It Will Use Claims Data for 340B Myeloma Drug Purchases

Bristol Myers Squibb has disclosed its terms of use for the drug claims data that providers must give it in exchange for access to 340B pricing on BMS’s oral oncology drugs Revlimid, Pomalyst, and Thalomid.

BMS acquired the three drugs when it acquired drug manufacturer Celgene in 2019. As described in a six-part 340B Report investigation last year, hospitals complained for years about Celgene’s 2015 limited distribution system for the three drugs and how the system kept them from accessing 340B pricing on the expensive medicines—Revlimid in particular, the most widely used of the three.

Bristol Myers Squibb has disclosed its terms of use for the drug claims data that providers must give it in exchange for access to 340B pricing on BMS’s oral oncology drugs Revlimid, Pomalyst, and Thalomid.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

×

*Sign up for news summaries and alerts from 340B Report

Site Footer